Navigating Supplements and Organic Foods

Treatment with an all-oral regimen led to three-year overall survival and relapse-free survival rates of 97% in patients with acute promyelocytic leukemia, a subset of acute myeloid leukemia.

From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.

A recent study showed that incorporating immunotherapy checkpoint blockade into treatment before and after surgery can increase treatment-related side effects.

"I’m on a healthy footing, and that’s pretty miraculous," said singer-songwriter Andrew McMahon, an acute lymphoblastic leukemia survivor and founder of the Dear Jack Foundation.

Following promising study results, a Biologics License Application has been filed with the FDA for obe-cel (obecabtagene autoleucel), a CAR-T cell therapy for patients with relapsed/refractory (r/r) adult B-cell acute lymphoblastic leukemia (ALL).

The FDA announced rare instances of secondary diseases or cancers from CAR-T cell therapy, though this is not the first time that oncology treatments have been associated with secondary diseases.